NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update NuCana (NASDAQ: NCNA) reported Q4 and full-year 2025 results and a clinical update on its ProTide pipeline. NUC-7738 showed clinical activity in PD-1 inhibitor-resistant melanoma with partial responses; final Phase 2 expansion data expected in 2026. Cash and equivalents were £24.3M at year‑end, supporting operations into 2029. The company reported a 2025 net loss of £29.4M, reflecting non-cash warrant revaluations and elevated share-based payments.Key near-term priorities include completing NuTide:701 enrollment, seeking FDA guidance on a registrational path, and advancing NUC-3373 combinations.

#NCNA NuCana Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/NCNA/nu-cana-report...

NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma NuCana (NASDAQ: NCNA) presented Phase 2 expansion data for NUC-7738 plus pembrolizumab at ESMO Immuno-Oncology Congress on Dec 10, 2025. The dataset in PD-1 inhibitor‑resistant metastatic melanoma shows clinical activity and a favorable safety profile.Key results: 2 partial responses (one confirmed), 7 stable disease cases including one ongoing stable disease that converted to a complete metabolic response, and no new safety signals. Nine patients have been treated in the Expansion Cohort; combined with 12 in the Dose Confirmation Cohort the program may include up to 40 patients.

#NCNA NuCana Presents Latest Data Demonstrating Clinical Activity and Favorable Safety for NUC-7738 in Patients with PD-1-Resistant Melanoma

www.stocktitan.net/news/NCNA/nu-cana-presen...

NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued Listing Criteria Well Capitalized with Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom,

#NCNA NuCana Reports Third Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/NCNA/nu-cana-report...

NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China NuCana (NASDAQ: NCNA) announced that the China National Intellectual Property Administration granted a composition‑of‑matter patent (ZL 202010794701.2) for NUC‑7738 on Nov 5, 2025.The patent covers the chemical structure of NUC‑7738 and is expected to be a key element of the program's IP protection, which now includes over 85 issued patents worldwide. NUC‑7738 is a novel anti‑cancer agent in a Phase 1/2 NuTide:701 study combining NUC‑7738 with pembrolizumab for patients with PD‑1 inhibitor refractory or resistant melanoma. The company cited encouraging clinical and translational findings presented at ESMO 2025 and said it aims to expand NuTide:701 to add patients and strengthen the data package.

#NCNA NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in China

www.stocktitan.net/news/NCNA/nu-cana-announ...

NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy NUC-3373 Plus Pembrolizumab Continues to Show Favorable Efficacy and Safety Profile in Heavily Pre-treated Patients Latest Data Cut-Off Shows Patient with Melanoma Remains Progression-Free at 23 Months with a Durable Partial Response Preclinical Data Corroborate Immunogenic Effects of NUC-3373

#NCNA NuCana Announces Encouraging Data for NUC-3373 in Combination with Anti-PD-1 Therapy

www.stocktitan.net/news/NCNA/nu-cana-announ...

Biotech NuCana Secures Nasdaq Future: Cash Runway Extended to 2029 After Meeting All Listing Requirements NuCana meets all Nasdaq listing criteria including $1.00 minimum bid requirement. Company's strengthened cash position from ATM offering supports operations through key milestones into 2029.

#NCNA NuCana Compliant with All Nasdaq Continued Listing Criteria

www.stocktitan.net/news/NCNA/nu-cana-compli...

NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update NuCana (NASDAQ: NCNA) has reported its Q2 2025 financial results and provided significant updates on its clinical development programs. The company has begun dosing patients in the expansion study of NUC-7738 combined with pembrolizumab for PD-1 inhibitor-resistant melanoma, with initial data expected in Q4 2025. The expansion will add 28 patients, bringing the total treated population to 40.Financially, NuCana has strengthened its position through an ATM offering and financing initiatives, raising $38.4 million in gross proceeds in 2025. The company reported cash and equivalents of £8.4 million as of June 30, 2025, with additional £19.0 million raised post-quarter. These actions have extended the company's cash runway into 2029. The quarter saw a net loss of £24.1 million, including a £12.6 million warrant revaluation loss.

#NCNA NuCana Reports Second Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/NCNA/nu-cana-report...

News; ( NASDAQ: #NCNA ) US Companies Moving the Markets, Evening edition <br>Mon, Aug 11, 2025 as of 4:00 pm ET

NEWS: ( NASDAQ: #NCNA ) US Companies Moving the Markets, Morning edition <br>Mon, Aug 11, 2025 as of 10.00 am ET

NuCana Announces ADS Ratio Change NuCana (NASDAQ: NCNA) has announced a significant change in its American Depositary Shares (ADS) ratio, effective August 11, 2025. The ratio will change from 1 ADS representing 25 ordinary shares to 1 ADS representing 5,000 ordinary shares.This adjustment effectively functions as a 1-for-200 reverse ADS split. The change aims to enhance ADS liquidity and help NuCana regain compliance with Nasdaq's minimum bid price requirement. While shareholders' proportional equity interest remains unchanged, the ADS trading price is expected to increase proportionally.The transition will be automatic for holders of uncertificated ADSs, while those holding certificated ADSs must surrender them to Citibank for exchange. Fractional ADSs will be sold, with proceeds distributed to affected holders.

#NCNA NuCana Announces ADS Ratio Change

www.stocktitan.net/news/NCNA/nu-cana-announ...

NuCana Announces Plan to Implement ADS Ratio Change NuCana (NASDAQ: NCNA) announced plans to implement a significant change in its American Depositary Shares (ADS) ratio. The company will modify the ratio from 1 ADS representing 25 ordinary shares to 1 ADS representing 5,000 ordinary shares, effective around August 8, 2025.This change effectively functions as a 1-for-200 reverse ADS split. The move aims to enhance ADS liquidity and help NuCana regain compliance with Nasdaq's minimum bid price requirement. While holders' proportional equity interest remains unchanged, the ADS trading price is expected to increase proportionally, though this is not guaranteed.

#NCNA NuCana Announces Plan to Implement ADS Ratio Change

www.stocktitan.net/news/NCNA/nu-cana-announ...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with declining money flow, Wed Jul 9th - #VACH #SEAT #PHH #NCNA #MITK #KRNY #GROW #FBIO #EOSE #DENN #BCTX #AIXI #PSFE #HCI #CBL - More: crystalequityresearch.com/SmCpStr/ - #smallcap

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks gapping down in trading Mon Jun 30th - #BBLG #VERI #UBX #SHLS #OST #NCNA #INMG #HSDT #ARBK #TROX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

NuCana Reports First Quarter 2025 Financial Results and Provides Business Update NuCana (NASDAQ: NCNA) reported Q1 2025 financial results and provided updates on its cancer drug pipeline. The company's lead program NUC-7738 has shown promising results in treating PD-1 inhibitor-resistant melanoma, leading to an expansion trial with 28 additional patients. NuCana's second program, NUC-3373, is showing positive data in combination with pembrolizumab for advanced solid tumors. The company reported a reduced net loss of £2.5 million in Q1 2025 compared to £6.8 million in Q1 2024. Following a May financing round raising £8.8 million, NuCana's cash position stands at £4.0 million, with runway extended into Q4 2026. Key upcoming milestones include data readouts from both NUC-7738 and NUC-3373 trials, and regulatory guidance from the FDA for NUC-7738's pivotal study in melanoma.

#NCNA NuCana Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/NCNA/nu-cana-report...

Pennies on the Rise: HCTI, SWISF, ADHC, NCNA Gain Traction Amid LargeCap Uncertainty – More Stocks Inside Getting your Trinity Audio player ready... In a market defined by uncertainty and shifting investor sentiment, a select group of penny stocks is making waves across healthcare, cybersecurity, biotech,...

#SWISF Sekur Private Data Ltd. note: Gaining traction
thestreetreports.com/pennies-on-t...
#ADHC #HCTI #NCNA

Just In: ( NASDAQ: #NCNA ) Expected US Company Earnings on Thursday, May 15th, 2025

Cancer Drug Developer NuCana Raises $7M: New Funding to Accelerate Treatment Breakthroughs Clinical-stage biotech NuCana prices complex securities offering to advance cancer drug pipeline. See detailed warrant terms and strategic use of proceeds.

#NCNA NuCana Prices $7 Million Registered Direct Offering

www.stocktitan.net/news/NCNA/nu-cana-prices...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Mon May 5th - #ZCAR #UCAR #KWE #KDLY #IVF #FMST #STEC #SBET #QNCX #NCNA #MRIN #IMMP #FNGR #CTRM #BCRX #AIFF #VCSA - More: crystalequityresearch.com/SmCpStr/ - #smallcap

NuCana's Melanoma Drug Breakthrough: 75% Disease Control Rate as Losses Shrink 31% NuCana's NUC-7738 achieves 75% disease control in melanoma patients while reducing annual losses by 31%. Cash runway extends to Q3 2025 with promising pipeline developments.

#NCNA NuCana Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/NCNA/nu-cana-report...

#NCNA NuCana Reports Third Quarter 2024 Financial Results and Provides Business Update

www.stocktitan.net/news/NCNA/nu-cana-report...

BREAKING NEWS: ( NASDAQ: #NCNA ) NuCana Presents Encouraging Data on NUC-7738 in Combination with Pembrolizumab in PD-1 Inhibitor Refractory and Resistant Melanoma Patients at the ESMO Congress 2024

#StockMarket #News